Receptor News and Research

RSS

TSRI scientists use new drug discovery technique to identify anti-diabetes compound

Scientists from The Scripps Research Institute have deployed a powerful new drug discovery technique to identify an anti-diabetes compound with a novel mechanism of action.

8 Dec 2015

Researchers reveal potential for exploring new treatment options for triple-negative breast cancer

Researchers from Caris Life Sciences and Fox Chase Cancer Center – Temple Health announced the presentation of two studies revealing the potential for exploring new therapeutic options for triple-negative breast cancer (TNBC) at the 2015 San Antonio Breast Cancer Symposium.

7 Dec 2015

OphthaliX completes patient enrollment in CF101 Phase II trial for treatment of glaucoma

OphthaliX Inc., a clinical-stage company focused on developing therapeutic products for the treatment of ophthalmic disorders and a subsidiary of Can-Fite BioPharma Ltd., announced today that it has completed patient enrollment for its Phase II trial of CF101 in the treatment of glaucoma.

7 Dec 2015

Ibrutinib more effective than traditional chemotherapy in older untreated patients with CLL

A multi-center, international, randomized, Phase III study of older untreated patients with chronic lymphocytic leukemia (CLL) demonstrated that ibrutinib, a kinase inhibitor, is significantly more effective than traditional chemotherapy with chlorambucil.

7 Dec 2015

Genetic variations associated with increased risk for osteonecrosis in young ALL patients

Variations in genes involved in normal bone development are associated with an 8- to 15-fold increased risk for osteonecrosis in young patients with acute lymphoblastic leukemia (ALL), according to research led by St. Jude Children's Research Hospital and Children's Oncology Group investigators.

7 Dec 2015

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

New research adds to a growing body of evidence that gene therapy, an experimental technique that involves correcting or replacing a person's mutated or malfunctioning genes, may improve health outcomes for patients with inherited bleeding and immune disorders as well as some forms of blood cancer.

7 Dec 2015

EKF biomarker identifies likely development of Diabetic Nephropathy

EKF, announces new data presented in support of soluble Tumour Necrosis Factor Receptor 1 as a biomarker to predict progression of Diabetic Nephropathy.

From EKF Diagnostics 2 Dec 2015

Combination therapy increases estrogen receptor positive breast cancer risk in African American women

Postmenopausal African American women who use female hormone supplements containing estrogen and progestin ("combination" therapy) are at an increased risk for estrogen receptor positive breast cancer.

1 Dec 2015

UofL researchers discover mechanism involved in skeletal muscle repair

Researchers at the University of Louisville have discovered a mechanism involved in skeletal muscle repair that may enable clinicians to boost the effectiveness of adult stem cell therapies for diseases such as muscular dystrophy.

1 Dec 2015

Heptares announces strategic drug discovery collaboration with Pfizer

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, announces that it has entered into a strategic drug discovery collaboration with Pfizer Inc. to research and develop potential new medicines directed at up to 10 G protein-coupled receptor (GPCR) targets across multiple therapeutic areas.

30 Nov 2015

Helsinn one step closer to bringing anamorelin HCI to market for treatment of anorexia, cachexia in NSCLC patients

Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announced that the European Medicines Agency accepted for review, the marketing authorization application (MAA) for anamorelin HCI, a novel, orally active selective ghrelin receptor agonist under development for the treatment of anorexia, cachexia, or unintended weight loss in non-small cell lung cancer (NSCLC) patients.

30 Nov 2015

Scientists show how malaria parasites invade the liver

Scientists at the Center for Infectious Disease Research recently uncovered a critical piece in the puzzle of how malaria parasites infect their host. The work, recently published in Science Magazine, reveals the details of how the malaria parasite invades its initial target organ, the liver. Without infection of the liver, the parasites cannot multiply or spread to the blood. Infection of the blood causes illness, spread of the disease, and, ultimately, death.

27 Nov 2015

Researchers successfully combine antibody-drug conjugate with immunotherapy to attack breast cancer cells

To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years. Researchers from the University and University Hospital Basel have now for the first time successfully combined such an antibody-drug conjugate with a therapy that stimulates the immune system to attack tumor cells.

26 Nov 2015

Liver's cannabinoid receptors could be targeted to combat liver cancer in some patients

A new study reveals that the liver's cannabinoid receptors could be targeted to fight liver cancer in some patients; and it offers a way to predict what treatments have the best chance of working.

23 Nov 2015

Atypical antipsychotic shows bipolar I depression efficacy

The atypical antipsychotic cariprazine may be effective for the treatment of bipolar I depression, phase II study findings show.

20 Nov 2015

Interaction between two brain proteins has substantial effect on memory formation

In a new study that could have implications for future drug discovery efforts for a number of neurodegenerative diseases, scientists from the Florida campus of The Scripps Research Institute (TSRI) have found that the interaction between a pair of brain proteins has a substantial and previously unrecognized effect on memory formation.

20 Nov 2015

Rockefeller University researchers discover molecule that helps guide axons during CNS development

During embryonic development, billions of neurons nimbly reposition themselves within the brain and spinal cord, and connect branches to form the neural circuits that ultimately control our movements, perception, and memory. Scientists have long sought to understand the driving forces in this meticulously choreographed dance, in which each cell seems to know precisely where to be to at any given time, and with what other cells it must link.

20 Nov 2015

New approach to regulate people's cholesterol levels

A discovery about how the body deals with the cholesterol contained within its dying cells has suggested an exciting new approach to control people's cholesterol levels - and thus their risk of developing heart disease.

19 Nov 2015

IQWiG finds no added benefit for insulin degludec/liraglutide in adults with type 2 diabetes

The fixed combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since June 2015 also in adults with type 2 diabetes mellitus when oral antidiabetics (OADs) combined with a GLP-1 receptor agonist do not provide adequate glycaemic control. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether this fixed combination offers an added benefit over the appropriate comparator therapy (ACT).

19 Nov 2015

Georgia State University researchers develop a method to better trace and treat cancer

A method to better trace changes in cancers and treatment of the prostate and lung without the limitations associated with radiation has been developed by Georgia State University researchers.

18 Nov 2015

Receptor News and Research

TSRI scientists use new drug discovery technique to identify anti-diabetes compound

Researchers reveal potential for exploring new treatment options for triple-negative breast cancer

OphthaliX completes patient enrollment in CF101 Phase II trial for treatment of glaucoma

Ibrutinib more effective than traditional chemotherapy in older untreated patients with CLL

Genetic variations associated with increased risk for osteonecrosis in young ALL patients

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

EKF biomarker identifies likely development of Diabetic Nephropathy

Combination therapy increases estrogen receptor positive breast cancer risk in African American women

UofL researchers discover mechanism involved in skeletal muscle repair

Heptares announces strategic drug discovery collaboration with Pfizer

Helsinn one step closer to bringing anamorelin HCI to market for treatment of anorexia, cachexia in NSCLC patients

Scientists show how malaria parasites invade the liver

Researchers successfully combine antibody-drug conjugate with immunotherapy to attack breast cancer cells

Liver's cannabinoid receptors could be targeted to combat liver cancer in some patients

Atypical antipsychotic shows bipolar I depression efficacy

Interaction between two brain proteins has substantial effect on memory formation

Rockefeller University researchers discover molecule that helps guide axons during CNS development

New approach to regulate people's cholesterol levels

IQWiG finds no added benefit for insulin degludec/liraglutide in adults with type 2 diabetes

Georgia State University researchers develop a method to better trace and treat cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News